ANI Pharmaceuticals has acquired the new drug applications (NDAs) and US marketing rights for AstraZeneca’s Atacand, Atacand HCT, Arimidex, and Casodex for $46.5m.
Atacand is an angiotensin II receptor blocker (ARB) indicated for the treatment of hypertension in adults and children 1 to <17 years of age, to lower blood pressure. The drug is also intended for the treatment of heart failure.
Atacand HCT is a combination of an angiotensin II receptor (type AT1) antagonist and a diuretic, hydrochlorothiazide. The drug has been indicated for the treatment of hypertension, to lower blood pressure.
Read more: http://bit.ly/AstraZenecaNDAs